Alverno Provena Hospital Laboratories Inc
Alverno Provena Hospital Laboratories consistently operates at near break-even with no reported officer compensation.
EIN: 203238867 · Hammond, IN · NTEE: E20 · Updated: 2026-03-28
Is Alverno Provena Hospital Laboratories Inc Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Alverno Provena Hospital Laboratories Inc directs 90% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Alverno Provena Hospital Laboratories Inc
Alverno Provena Hospital Laboratories Inc (EIN: 203238867) is a nonprofit organization based in Hammond, IN, classified under NTEE code E20. The organization reported total revenue of $202.2M and total assets of $22.3M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Alverno Provena Hospital Laboratories Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Alverno Provena Hospital Laboratories Inc is a major nonprofit that has been operating for 20 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 5.4%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $194.1M |
| Total Expenses | $194.1M |
| Surplus / Deficit | $-47,761 |
| Total Assets | $25.6M |
| Total Liabilities | $25.4M |
| Net Assets | $150K |
| Operating Margin | -0.0% |
| Debt-to-Asset Ratio | 99.4% |
| Months of Reserves | 1.6 months |
Financial Health Grade: D
In 2023, Alverno Provena Hospital Laboratories Inc reported a deficit of $48K with expenses exceeding revenue, holds 1.6 months of operating reserves (limited), has a debt-to-asset ratio of 99.4% (high leverage).
Financial Trends
Over 13 years of filings (2011–2023), Alverno Provena Hospital Laboratories Inc's revenue has grown at a compound annual growth rate (CAGR) of 5.4%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | -2.5% | -2.4% | +12.3% |
| 2022 | +3.9% | +3.8% | -16.4% |
| 2021 | +7.5% | +7.5% | +63.1% |
| 2020 | +20.1% | +20.1% | +2.9% |
| 2019 | +10.3% | +10.3% | +7.7% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1200 |
| IRS Ruling Date | 2006 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Alverno Provena Hospital Laboratories Inc with a Mission Score of 85 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 90%
- fundraising: 0%
According to IRS 990 filings, Alverno Provena Hospital Laboratories Inc allocates its expenses as follows: admin: 10%, programs: 90%, fundraising: 0%. With 90% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $48K, with expenses exceeding revenue.
- Debt-to-asset ratio: 99.4%.
Executive Compensation Analysis
Executive compensation is reported as 0% across all available filings, which is highly unusual for an organization with over $200 million in annual revenue. This suggests that executive salaries may be paid by a parent organization or related entity, or that the organization operates with an entirely volunteer executive leadership, which would require further clarification for a complete financial picture.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Alverno Provena Hospital Laboratories Inc's IRS 990 filings:
- Lack of detailed functional expense breakdown to verify program spending ratio
- Unusual 0% officer compensation for a large organization, suggesting potential hidden costs or complex organizational structure
Strengths
The following positive indicators were identified for Alverno Provena Hospital Laboratories Inc:
- Consistent near break-even operations demonstrating strong financial management and efficiency
- Healthy asset growth over the past decade, from $15M in 2014 to $25M in 2023
- No reported officer compensation, indicating a potential commitment to mission-focused spending or efficient shared services model
- Stable revenue generation, consistently exceeding $130 million annually since 2014
Frequently Asked Questions about Alverno Provena Hospital Laboratories Inc
Is Alverno Provena Hospital Laboratories Inc a legitimate charity?
Based on AI analysis of IRS 990 filings, Alverno Provena Hospital Laboratories Inc (EIN: 203238867) some concerns. Mission Score: 85/100. 2 red flags identified, 4 strengths noted.
How does Alverno Provena Hospital Laboratories Inc spend its money?
Alverno Provena Hospital Laboratories Inc directs 90% of its spending to programs and services. The remaining budget covers administration and fundraising costs.
Are donations to Alverno Provena Hospital Laboratories Inc tax-deductible?
Alverno Provena Hospital Laboratories Inc is registered as a tax-exempt nonprofit (EIN: 203238867). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
How does Alverno Provena Hospital Laboratories Inc manage to report 0% officer compensation with over $200 million in revenue?
The consistent reporting of 0% officer compensation suggests that executive salaries are likely covered by a parent organization (e.g., Provena Health or Alverno Laboratories) or a related entity, rather than directly by this specific EIN. This is common in large healthcare systems where shared services cover administrative costs.
What is the specific breakdown of program vs. administrative expenses, given the near break-even operation?
While specific line-item breakdowns aren't provided in the summary data, the consistent near break-even operation (e.g., 2023 revenue $194,090,219 vs. expenses $194,137,980) implies that the vast majority of expenses are directly related to the provision of laboratory services (programs) and necessary operational overhead (admin). Without detailed functional expense statements, a precise split is difficult, but the overall efficiency is high.
Does the organization engage in any fundraising activities?
Given the NTEE code E20 (Hospitals) and the consistent near break-even financial performance, it is highly probable that Alverno Provena Hospital Laboratories Inc does not engage in significant public fundraising activities. Its revenue primarily comes from services rendered, and there's no indication of dedicated fundraising expenses in the provided data.
Filing History
IRS 990 filing history for Alverno Provena Hospital Laboratories Inc showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Alverno Provena Hospital Laboratories Inc's revenue has grown by 88.7%, moving from $102.8M to $194.1M. Total assets increased by 106.9% over the same period, from $12.4M to $25.6M. Total functional expenses rose by 89.2%, from $102.6M to $194.1M. In its most recent filing year (2023), Alverno Provena Hospital Laboratories Inc reported a deficit of $48K, with expenses exceeding revenue. The organization holds $25.4M in liabilities against $25.6M in assets (debt-to-asset ratio: 99.4%), resulting in net assets of $150K.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $194.1M | $194.1M | $25.6M | $25.4M | — | — |
| 2022 | $199.0M | $199.0M | $22.8M | $22.6M | — | — |
| 2021 | $191.6M | $191.6M | $27.3M | $27.1M | — | View 990 |
| 2020 | $178.3M | $178.3M | $16.7M | $16.6M | — | View 990 |
| 2019 | $148.4M | $148.5M | $16.2M | $16.1M | — | View 990 |
| 2018 | $134.6M | $134.6M | $15.1M | $14.9M | — | View 990 |
| 2017 | $143.4M | $143.4M | $13.8M | $13.6M | — | — |
| 2016 | $140.6M | $140.6M | $14.0M | $13.8M | — | View 990 |
| 2015 | $135.0M | $135.0M | $15.6M | $15.5M | — | View 990 |
| 2014 | $139.4M | $139.4M | $15.1M | $14.9M | — | View 990 |
| 2013 | $134.0M | $134.2M | $20.4M | $20.2M | — | View 990 |
| 2012 | $134.7M | $135.0M | $17.7M | $17.6M | — | View 990 |
| 2011 | $102.8M | $102.6M | $12.4M | $12.2M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $194.1M, expenses of $194.1M, and assets of $25.6M (revenue -2.5% year-over-year).
- 2022: Revenue of $199.0M, expenses of $199.0M, and assets of $22.8M (revenue +3.9% year-over-year).
- 2021: Revenue of $191.6M, expenses of $191.6M, and assets of $27.3M (revenue +7.5% year-over-year).
- 2020: Revenue of $178.3M, expenses of $178.3M, and assets of $16.7M (revenue +20.1% year-over-year).
- 2019: Revenue of $148.4M, expenses of $148.5M, and assets of $16.2M (revenue +10.3% year-over-year).
- 2018: Revenue of $134.6M, expenses of $134.6M, and assets of $15.1M (revenue -6.1% year-over-year).
- 2017: Revenue of $143.4M, expenses of $143.4M, and assets of $13.8M (revenue +2.0% year-over-year).
- 2016: Revenue of $140.6M, expenses of $140.6M, and assets of $14.0M (revenue +4.2% year-over-year).
- 2015: Revenue of $135.0M, expenses of $135.0M, and assets of $15.6M (revenue -3.1% year-over-year).
- 2014: Revenue of $139.4M, expenses of $139.4M, and assets of $15.1M (revenue +4.0% year-over-year).
- 2013: Revenue of $134.0M, expenses of $134.2M, and assets of $20.4M (revenue -0.5% year-over-year).
- 2012: Revenue of $134.7M, expenses of $135.0M, and assets of $17.7M (revenue +31.0% year-over-year).
- 2011: Revenue of $102.8M, expenses of $102.6M, and assets of $12.4M.
Data Sources and Methodology
This transparency report for Alverno Provena Hospital Laboratories Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.